Genevant scores with Takeda again as LNPs continue to attract interest for RNA therapy
Barely five months after signing on to a $600 million deal with Takeda, Genevant has returned to ink another big biobuck tie-up with its new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
